Live Webinar on Trop-2 ADCs in breast and lung cancers (May 7th)

PROGRAM OVERVIEW

Although immunotherapy has dramatically expanded the treatment landscape for a range of advanced cancers, there are several subtypes, including certain breast and lung cancers, that remain resistant to standard treatments and for which treatment options are limited. As a result, many patients continue to experience declining response rates, disease control, and quality of life (QoL). Nevertheless, efforts to identify novel approaches for addressing these significant unmet needs are ongoing. One approach that has shown a great deal of promise and has garnered significant attention recently is the use of antibody-drug conjugates (ADCs) that target Trop-2, a transmembrane glycoprotein that is upregulated in many cancers. By taking advantage of monoclonal antibodies selective for Trop-2, these agents enable the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells. There is currently only one Trop-2 ADC that has been approved by the FDA (for TNBC and HR+/HER2- BC [BC]). However, evidence continues to emerge in support of the use of multiple Trop-2 ADCs in not only these cancers, but others as well.

Join Dr. Aditya Bardia as he dives deeper into the current data on Trop-2 ADCs, providing the knowledge and skills needed to appropriately incorporate these therapies into evidence-based treatment plans as they are approved.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Describe the rationale for Trop-2 ADCs for the treatment of breast and lung cancer
• Review current and emerging evidence supporting the use of Trop-2 ADCs for the treatment of TNBC, HR+/HER2- BC, and NSCLC
• Design evidence-based plans for the treatment of TNBC, HR+/HER2- BC, and NSCLC employing Trop-2 ADCs

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM.